CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tagrisso osimertinib Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Takhzyro lanadelumab Hereditary angioedema, prevention Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Taltz Ixekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Talzenna talazoparib Metastatic castration-resistant prostate cancer (mCRPC) Suspended
Talzenna talazoparib Breast cancer CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Tarceva Erlotinib Cancer, Lung , non-small cell List with clinical criteria and/or conditions Complete
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Targin Oxycodone HCI / naloxone HCI Pain, moderate to severe and relief of opioid-induced constipation Do not list Complete
Tavalisse fostamatinib Chronic immune thrombocytopenia Do not reimburse Complete
Tavneos avacopan Antineutrophil cytoplasmic antibody-associated vasculitis Do not reimburse Complete
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
TBC filgotinib Arthritis, Rheumatoid Withdrawn
TBC risperidone Schizophrenia, adults Suspended
TBC ruxolitinib atopic dermatitis Suspended
TBC sotatercept Pulmonary arterial hypertension (WHO group 1) Active
TBC eplontersen Polyneuropathy in hereditary transthyretin-mediated amyloidosis Active
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Active
TBC zilucoplan Generalized myasthenia gravis (gMG) Suspended
TBC rozanolixizumab Generalized myasthenia gravis (gMG). Pending
TBC avapritinib Advanced Systemic Mastocytosis Active
TBC fruquintinib Metastatic colorectal cancer (mCRC) Active
TBC lebrikizumab atopic dermatitis Active
Last Updated : June 30, 2024